* OPDIVO PLUS LOW-DOSE YERVOY COMBINATION REDUCES THE RISK OF PROGRESSION OR DEATH BY 42% VERSUS CHEMOTHERAPY IN FIRST-LINE LUNG CANCER PATIENTS WITH HIGH TUMOR MUTATIONAL BURDEN (TMB)


80


Reuters

16 Related Articles, between 2018-03-22 and 2018-04-16